Bowling Portfolio Management LLC lessened its stake in Biogen Inc (NASDAQ:BIIB) by 74.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,175 shares of the biotechnology company's stock after selling 12,393 shares during the period. Bowling Portfolio Management LLC's holdings in Biogen were worth $1,212,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the stock. Parnassus Investments CA bought a new stake in shares of Biogen in the second quarter worth $15,963,000. HL Financial Services LLC increased its stake in shares of Biogen by 59.2% in the second quarter. HL Financial Services LLC now owns 7,504 shares of the biotechnology company's stock worth $2,178,000 after buying an additional 2,791 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Biogen by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 2,362,136 shares of the biotechnology company's stock worth $685,588,000 after buying an additional 72,668 shares during the last quarter. Quest Investment Management LLC increased its stake in shares of Biogen by 7.0% in the second quarter. Quest Investment Management LLC now owns 45,899 shares of the biotechnology company's stock worth $13,322,000 after buying an additional 3,018 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its stake in shares of Biogen by 51.4% in the second quarter. Teacher Retirement System of Texas now owns 119,014 shares of the biotechnology company's stock worth $34,543,000 after buying an additional 40,411 shares during the last quarter. Institutional investors and hedge funds own 91.34% of the company's stock. Get Biogen alerts:
A number of analysts recently issued reports on the stock. Cantor Fitzgerald set a $293.00 price target on shares of Biogen and gave the stock a "hold" rating in a research note on Wednesday, July 25th. UBS Group lifted their price target on shares of Biogen from $354.00 to $395.00 and gave the stock a "buy" rating in a research note on Thursday, July 26th. Citigroup lifted their price target on shares of Biogen to $483.00 and gave the stock a "positive" rating in a research note on Thursday, July 26th. Barclays boosted their target price on shares of Biogen from $295.00 to $320.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 25th. Finally, Robert W. Baird boosted their target price on shares of Biogen from $323.00 to $348.00 and gave the company a "neutral" rating in a research note on Wednesday, July 25th. Nine research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of "Buy" and a consensus target price of $374.50.
Biogen stock opened at $342.93 on Friday. The stock has a market cap of $69.09 billion, a PE ratio of 15.72, a PEG ratio of 1.46 and a beta of 0.89. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.36 and a quick ratio of 2.06. Biogen Inc has a one year low of $249.17 and a one year high of $388.67.
Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Tuesday, July 24th. The biotechnology company reported $5.80 EPS for the quarter, topping the consensus estimate of $5.22 by $0.58. The business had revenue of $3.36 billion during the quarter, compared to analyst estimates of $3.25 billion. Biogen had a net margin of 23.06% and a return on equity of 38.17%. The company's quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.04 earnings per share. equities research analysts predict that Biogen Inc will post 25.35 EPS for the current year.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. Biogen Bioge